Healius Ltd (ASX: HLS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Healius Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $697.09 million
P/E Ratio 55.56
Dividend Yield 0.00%
Shares Outstanding 726.13 million
Earnings per share -0.775
Dividend per share 0.12
Year To Date Return 14.92%
Earnings Yield 1.80%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Healius Ltd (ASX: HLS)
    Latest News

    A man looking at his laptop and thinking.
    Share Market News

    5 things to watch on the ASX 200 on Thursday

    Here's what to expect on the local market today.

    Read more »

    A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
    Healthcare Shares

    Analysts reveal 3 ASX healthcare shares to sell

    In FY26 so far, ASX 200 healthcare shares have fallen 4.1% while the benchmark index has lifted 4.6%.

    Read more »

    a man clasps his hand to his forehead as he looks down at his phone and grimaces with a pained expression on his face as he watches the Pilbara Minerals share price continue to fall
    Earnings Results

    Why did this ASX 200 healthcare stock crash 14% yesterday?

    Torrid day for shareholders.

    Read more »

    Shot of a young businesswoman looking stressed out while working in an office.
    Share Fallers

    Why Goodman, Healius, IPH, and Sonic Healthcare shares are falling today

    These shares are having a tough session on Thursday. But why?

    Read more »

    Medical workers examine an xray or scan in a hospital laboratory.
    Share Market News

    CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August

    Will these results be healthy?

    Read more »

    Two brokers analysing stocks.
    Small Cap Shares

    Broker tips these 3 ASX small-cap healthcare stocks to rise 56%, 79% and 130%

    These 3 ASX small-cap stocks could deliver substantial returns.

    Read more »

    A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
    ETFs

    The long game: ASX ETFs to target amidst an ageing population

    These funds could be set to benefit from increased demand in global healthcare. 

    Read more »

    Two brokers pointing and analysing a share price.
    Share Market News

    Here are the ASX 20, ASX 50, ASX 100, and ASX 200 shares being added and kicked out of their indices

    Let's see what changes are being made at this month's quarterly rebalance.

    Read more »

    Happy man working on his laptop.
    Share Market News

    5 things to watch on the ASX 200 on Tuesday

    Here's what to watch on the benchmark index today.

    Read more »

    Red sell button on an Apple keyboard.
    Broker Notes

    Sell alert! Brokers say pull the plug on these 3 ASX 200 shares

    Experts say it's time to press the sell button on these ASX 200 shares. Find out why.

    Read more »

    a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
    Share Fallers

    The 5 worst performing ASX 200 shares in May unmasked

    These five ASX 200 shares got smashed in May. But why?

    Read more »

    Cropped shot of an attractive young female scientist working on her computer in the laboratory.
    Healthcare Shares

    Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

    Macquarie updated its target price on these three ASX All Ords healthcare stocks.

    Read more »

    Frequently Asked Questions

    Yes, Healius has historically paid two fully franked shareholder dividends a year.

    Healius has generally paid its shareholder dividends in March/April and September/October.

    Healius Ltd listed on the ASX on 3 July 1998.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    09 May 2025 $0.4130 100.00% Special Cash 23 May 2025
    07 Sep 2022 $0.0600 100.00% Final 21 Sep 2022
    24 Mar 2022 $0.1000 100.00% Interim 05 Apr 2022
    13 Sep 2021 $0.0675 100.00% Final 08 Oct 2021
    25 Mar 2021 $0.0650 100.00% Interim 15 Apr 2021
    26 Mar 2020 $0.0260 100.00% Interim 15 Oct 2020
    29 Aug 2019 $0.0340 100.00% Final 27 Sep 2019
    15 Mar 2019 $0.0380 100.00% Interim 26 Mar 2019
    27 Aug 2018 $0.0550 100.00% Final 17 Sep 2018
    16 Mar 2018 $0.0510 100.00% Interim 27 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 18 Sep 2017
    17 Mar 2017 $0.0480 100.00% Interim 28 Mar 2017
    01 Sep 2016 $0.0640 100.00% Final 19 Sep 2016
    18 Mar 2016 $0.0560 50.00% Interim 29 Mar 2016
    26 Aug 2015 $0.1100 50.00% Final 14 Sep 2015
    18 Mar 2015 $0.0900 100.00% Interim 07 Apr 2015
    27 Aug 2014 $0.1100 100.00% Final 15 Sep 2014
    17 Mar 2014 $0.0900 100.00% Interim 07 Apr 2014
    16 Sep 2013 $0.1100 100.00% Final 08 Oct 2013
    18 Mar 2013 $0.0650 100.00% Interim 08 Apr 2013
    17 Sep 2012 $0.0600 100.00% Final 08 Oct 2012
    26 Mar 2012 $0.0500 100.00% Interim 16 Apr 2012
    19 Sep 2011 $0.0500 100.00% Final 10 Oct 2011
    21 Mar 2011 $0.0300 100.00% Interim 11 Apr 2011
    20 Sep 2010 $0.1000 100.00% Final 11 Oct 2010
    05 Mar 2010 $0.1500 100.00% Interim 29 Mar 2010
    07 Sep 2009 $0.0700 100.00% Final 28 Sep 2009
    16 Feb 2009 $0.0700 100.00% Interim 09 Mar 2009
    08 Sep 2008 $0.0500 100.00% Final 09 Oct 2008
    22 Feb 2008 $0.2200 100.00% Interim 17 Mar 2008
    31 Aug 2007 $0.2400 100.00% Final 24 Sep 2007
    09 Mar 2007 $0.2100 100.00% Interim 02 Apr 2007
    09 Oct 2006 $0.0800 100.00% Special Cash 30 Oct 2006
    04 Sep 2006 $0.2200 100.00% Final 25 Sep 2006
    20 Feb 2006 $0.2000 100.00% Interim 13 Mar 2006
    22 Aug 2005 $0.1300 100.00% Final 12 Sep 2005
    08 Apr 2004 $0.0750 100.00% Interim 03 May 2004

    HLS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Healius Ltd

    Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.

    The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres. 

    The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics. 

    HLS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    15 Jan 2026 $0.96 $-0.06 -5.88% 2,462,867 $1.03 $1.03 $0.95
    14 Jan 2026 $1.02 $-0.02 -1.92% 3,217,231 $1.04 $1.05 $1.01
    13 Jan 2026 $1.04 $0.04 4.00% 2,732,665 $1.00 $1.05 $1.00
    12 Jan 2026 $1.00 $0.03 3.08% 1,668,066 $0.97 $1.01 $0.97
    09 Jan 2026 $0.98 $0.02 2.09% 1,281,209 $0.96 $0.98 $0.95
    08 Jan 2026 $0.96 $0.01 1.05% 4,892,223 $0.94 $0.97 $0.94
    07 Jan 2026 $0.95 $0.05 5.59% 1,849,685 $0.90 $0.96 $0.90
    06 Jan 2026 $0.90 $0.00 0.00% 2,490,286 $0.88 $0.91 $0.85
    05 Jan 2026 $0.90 $-0.02 -2.20% 1,170,408 $0.92 $0.93 $0.89
    02 Jan 2026 $0.91 $0.01 1.10% 541,682 $0.91 $0.92 $0.91
    31 Dec 2025 $0.91 $-0.01 -1.09% 394,681 $0.92 $0.92 $0.90
    30 Dec 2025 $0.92 $-0.01 -1.09% 523,638 $0.92 $0.93 $0.91
    29 Dec 2025 $0.92 $-0.02 -2.14% 795,453 $0.94 $0.95 $0.92
    24 Dec 2025 $0.94 $-0.02 -2.09% 393,176 $0.96 $0.96 $0.94
    23 Dec 2025 $0.96 $0.01 1.06% 595,025 $0.95 $0.97 $0.95
    22 Dec 2025 $0.95 $-0.01 -1.05% 718,533 $0.96 $0.97 $0.94
    19 Dec 2025 $0.95 $0.00 0.00% 4,971,181 $0.96 $0.97 $0.94
    18 Dec 2025 $0.95 $-0.02 -2.07% 2,745,556 $0.97 $0.97 $0.92
    17 Dec 2025 $0.97 $-0.01 -1.03% 2,833,040 $0.98 $0.99 $0.95
    16 Dec 2025 $0.98 $0.00 0.00% 1,286,623 $0.98 $0.99 $0.96

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Nov 2025 Paul Anderson Buy 54,431 $47,899
    On-market trade.
    10 Nov 2025 Katherine (Kathy) Ostin Issued 45,955 $39,999
    Director remuneration. VWAP, 45,955 Share Rights
    31 Oct 2025 Paul Anderson Buy 57,471 $50,976
    On-market trade.
    29 Aug 2025 Neil Vinson Buy 17,045 $14,999
    On-market trade. Average price
    28 Aug 2025 Katherine (Kathy) Ostin Buy 21,779 $20,036
    On-market trade. Average price
    28 Aug 2025 Katherine (Kathy) Ostin Buy 2,000 $1,840
    On-market trade. Average price
    27 Aug 2025 John Mattick Buy 200,000 $182,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Christopher John Hall Non-Executive Director Sep 2025
    Mr Hall has included roles as Chair, Non-Executive Director and Chief Investment Officer, along with senior executive positions in Australia and Hong Kong. Mr Halls current roles include Chair of BiomeBank, Non-Executive Director, Investment Committee Member and Audit Committee Member of AMP Superannuation, Non-Executive Director and Audit Committee Member of Funds SA, Investment Committee Chair of Perks Private Wealth, and Member of the Advisory Board to the Long-Term Value Fund at Tanarra Capital.
    Professor John Mattick Non-Executive Director Mar 2022
    Professor Mattick was Chief Executive of Genomics England, which was established by the United Kingdom government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established high throughput NATA accredited DNA sequencing and genome analysis facilities. He was a member of the Australian Health Ethics Committee (AHEC) of the National Health & Medical Research Council (NHMRC) from 1997 to 2003, an advisor to the Australian Law Reform Commissions Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He was appointed an Officer of the Order of Australia in 2001 for services to scientific research in the fields of molecular biology, genetics and biotechnology. He is a member of the Risk Management Committees.
    Mr Paul Anderson Chief Executive OfficerManaging Director Mar 2024
    Mr Anderson was appointed as Chief Executive Officer in March 2024. Prior to this, he held the position of Group Chief Financial Officer of Healius. He is an experienced business leader with a background in industries facing significant disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & New Zealand. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.
    Ms Kathryn (Kate) Mary McKenzie Non-Executive ChairmanNon-Executive Director Feb 2021
    Ms McKenzie is a member of the Boards Risk Management Committee and People, Governance and Remuneration Committee. She is an experienced Chief Executive Officer and Non Executive Director. Her executive career included over 30 years of experience in the telecommunication and government sectors in Australia, New Zealand and Hong Kong. She was most recently the Chief Executive Officer of Chorus. Prior to this, she held several senior roles at Telstra, including Chief Operating Officer, where she oversaw the groups property portfolio, and seven years in senior roles in NSW Government, including the Department of Commerce and Department of Industrial Relations. She is a member of Chief Executive Women, has served on the Telstra Foundation.
    Ms Sally Evans Non-Executive Director Aug 2018
    Ms Evans was appointed as a Non Executive Director. She is the Chair of the Boards People, Governance and Remuneration Committee and is a member of the Risk Management Committee. She has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region.
    Ms Katherine (Kathy) Ostin Non-Executive Director Dec 2024
    Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG and has experience in the aged care and healthcare sectors, having established and led KPMGs Health, Aging and Human Services audit practice. During her 24 years with KPMG, she worked in Australia, the US, Asia and UK. She is a member of the People and Governance Committee.
    Mr Charlie Taylor Non-Executive Director Mar 2023
    Mr Taylor has over 30 years of experience in international advisory having recently retired as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australias private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. He initiated multiyear research efforts on healthcare, COVID response, productivity and innovation and has published research articles and reports on healthcare reform lessons from around the globe. He is currently a part time senior board advisor at McKinsey for the Health and Public Sector practice, a member of the strategic advisory committee For Purpose Investment Partners and was recently appointed as Chair of the NSW Innovation and Productivity Commission. He is the Honorary Federal Treasurer for the Liberal Party and a Board member on the Federal Executive. He is a member of both the People and Governance Committees.
    Mr Steven Rubic Non-Executive Director Dec 2025
    Mr Rubic will bring to the Board 25 years of executive leadership in healthcare. He has held CEO positions at St Vincents and Mater Health Sydney, I-MED Radiology Network and Healthscope. He is also a Non-Executive Director. Mr Rubic is currently a Non Executive Director of the Mater Hospitals Group, Pacific Smiles Group Limited (ASX:PSQ) and Catholic Healthcare Limited. He is also Deputy Chair of TPG private equity owned InvoCare.
    Hon Andrew Peter Thomson Company Secretary Oct 2025
    -
    Ms Kylie Brown Company Secretary May 2025
    -
    Puneet Nagi Chief Operating Officer
    -
    Andrew Peter Thomson Company Secretary
    -
    Kylie Brown Company Secretary
    -
    Rodney Rudling Group Executive Clinical Integration
    -
    Anthea Muir Group Executive Customer & Commercial
    -
    Prasad Arav Group Executive Digital & Technology and Strategy
    -
    Arjun Narang Group Executive Operations
    -
    Paula Bayliss Group Executive People & Culture
    -
    Kylie Brown Group General Counsel Company Secretary and Chief Risk Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 222,504,649 30.64%
    Citicorp Nominees Pty Limited 195,963,913 26.99%
    J P Morgan Nominees Australia Pty Limited 77,855,084 10.72%
    BNP Paribas Noms Pty Ltd 38,424,201 5.29%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Supercorp A/C> 11,786,784 1.62%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 11,238,922 1.55%
    Argo Investments Limited 10,874,452 1.50%
    First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> 9,181,310 1.26%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 3,309,503 0.46%
    Lsnd Pty Ltd <Lsnd A/C> 2,787,659 0.38%
    Rinrim Pty Ltd 2,497,161 0.34%
    Anacacia Pty Ltd <Wattle Fund A/C> 2,450,000 0.34%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 2,267,035 0.31%
    Ubs Nominees Pty Ltd 2,124,074 0.29%
    Neweconomy Com Au Nominees Pty Limited <900 Account> 2,076,697 0.29%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 1,992,066 0.27%
    Gsa Custodians Pty Ltd <The Gsa Global Unit A/C> 1,250,000 0.17%
    Mr Edgard Zoghbi 1,200,000 0.17%
    Mr William Alan Cosgrove + Mrs Joan Iris Cosgrove <Hawthorn Super Fund A/C> 1,000,000 0.14%
    Ocean Capital Pty Limited 1,000,000 0.15%

    Profile

    since

    Note